Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform
What You Should Know:
– Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing…
Continue Reading